VCYT vs VRTX: fair value comparison
Veracyte, Inc. and Vertex Pharmaceuticals Incorporated · Updated 2026-09-07
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, VRTX currently sits closer to the top of our discount ranking.
| VCYT | VRTX | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $44.85 | $546.12 |
| 12-month range | $32.40–$59.85 | $423.92–$547.65 |
| Sector rank | #84 of 113 Healthcare | #82 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: VCYT fair value analysis · VRTX fair value analysis